Introduction and objective {#S0001}
==========================

Human leukocyte antigen B27 (HLA-B27) is strongly associated with spondyloarthropathies, especially with ankylosing spondylitis (AS). HLA-B27 testing is routinely applied in the diagnosis of this disease. In the Caucasian race, HLA-B27 is present in 90% of patients suffering from AS, whereas among a healthy population it is present in 3% to 9% of individuals \[[@CIT0001]\].

HLA-B27 has 105 currently known subtypes encoded by 132 allelic variants \[[@CIT0002]\]. Not every allelic variant is disease-associated, and the strength of the association varies dependently on type of spondyloarthropathy and ethnicity of carriers. In the Caucasian race the 27:05 subtype is very strongly associated with AS \[[@CIT0003]\]. Moreover, this subtype is the most widely distributed one in the Polish population \[[@CIT0004]\]. Association with AS occurrence has been observed for 27:01-05, 27:07, 27:08, 27:10, 27:13-15, 27:19, 27:23, 27:24, 27:25 and 27:49 subtypes \[[@CIT0002]\]. Some subtypes are not associated with increased risk of AS (27:09) or may play a protective role (27:06) \[[@CIT0002], [@CIT0005]\].

The most widely used diagnostic method of HLA-B27 determination is the flow cytometry assay. In this assay, HLA-B27 on the T cell surface is detected using a specific monoclonal antibody. However, this method does not allow one to discriminate HLA-B27 allelic variants, which may be crucial for proper diagnosis. Analysis of HLA-B27 subtypes is possible only by means of genetic methods. The objective of the present study was to compare two methods of HLA-B27 detection: a flow cytometry assay and a genetic sequence-based method enabling distinction of allelic variants.

Material and methods {#S0002}
====================

Blood samples {#S20003}
-------------

Peripheral blood was obtained from 300 patients with suspected spondyloarthropathy. All patients gave their written informed consent according to the Declaration of Helsinki. The study was approved by the Institute of Rheumatology Ethics Committee, Warsaw, Poland. Peripheral blood samples (5 ml) were acquired in K~3~EDTA. One part of every sample was analysed by flow cytometry, and another part was frozen at --70°C. After refreezing, DNA was isolated from 200 µl of blood (QIAamp DNA Blood Mini Kit, Qiagen, Germantown, MD, USA) and then used in polymerase chain reaction.

Flow cytometry analysis {#S20004}
-----------------------

The presence of HLA-B27 on peripheral blood T cells was detected by GS145.2 monoclonal antibody (HLA-B27 Kit, Becton Dickinson, San Jose, CA, USA). The whole procedure was performed according to the manufacturer\'s instructions. Blood samples were stained with anti-HLA-B27 antibody conjugated with fluorescein and with anti-CD3 antibody conjugated with phycoerythrin. Samples were incubated for 20 min in the dark, at room temperature, and then analysed using a FACSCalibur flow cytometer and HLA-B27 v3.1 software (Becton Dickinson, San Jose, CA, USA).

Polymerase chain reaction {#S20005}
-------------------------

Isolated DNA (75 ng) was amplified using 1.25 U of Taq polymerase (Genoplast, Pruszków, Poland) and the MW02/MW09 primer pair \[[@CIT0006]\]. These primers amplify a 666-bp fragment of human HLA-B27, -B40 and -B47:01 genes. The MW02 sequence is located in exon 2, whereas MW09 is located in exon 3 of target genes. A 268-bp fragment of human β-globin was also amplified as an amplification control. The final volume of reaction mix was 25 µl, Mg^2+^ concentration -- 2 mM and deoxynucleotide triphosphates concentration -- 400 µM. Both primer pairs were used in 0.625 µM concentration. Each sample was pre-incubated at 95°C for 3 min before cycling. The thermal profile of the reaction was: 35 s at 95°C, 45 s at 57°C and 45 s at 72°C. After 30 cycles, 8 minutes of final elongation at 72°C completed the cycling program.

Samples that gave ambiguous results were additionally analysed using the E91/E136 primer pair (in a final concentration of 0.625 µM) amplifying a 135-bp fragment of the human HLA-B27 gene \[[@CIT0007]\]. Both primers are localized in exon 3 of the HLA-B27 gene. The final reaction volume and concentration of reagents were similar as in previous reactions. The thermal profile was as follows: pre-incubation of samples at 95°C for 5 min, 30 cycles composed of 45 s at 95°C, 60 s at 64°C, 60 s at 72°C and 7 minutes of final elongation at 72°C. Primer sequences, localization and specificity are given in [Table I](#T0001){ref-type="table"}.

###### 

Sequences, localization and specificity of the primers

  Primer             Localization   Sequence                      Specificity
  ------------------ -------------- ----------------------------- --------------------------------------------------------
  MW02 forward       exon 2         5'-GCTACGTGGACGACACGCT-'3     
  MW09 reverse       exon 3         5'-GAGCCACTCCACGCACTC-'3      HLA-B27[\*](#TF0001){ref-type="table-fn"}, B40, B47:01
  MW16 forward       exon 2         5'-CGCCGCGAGTCCGAGAGA-'3      HLA-B27
  E91 forward        exon 3         5'-GGGTCTCACACCCTCCAGAAT-'3   
  E136 reverse       exon 3         5'-CGGCGGTCCAGGAGCT-'3        HLA-B27[\*\*](#TF0002){ref-type="table-fn"}
  β-globin forward                  5'-CAACTTCATCCACGTTCACC-'3    
  β-globin reverse                  5'-GAAGAGCCAAGGACAGGTAC-'3    β-globin

excluding allelic variants: 27:15, 27:25, 27:28, 27:38, 27:47, 27:62, 27:63, 27:71, 27:76

excluding allelic variants: 27:07, 27:14, 27:19, 27:21.

Polymerase chain reaction products were size fractionated on 1.5% or 2% agarose gel (Genoplast, Pruszków, Poland) with addition of ethidium bromide (Sigma-Aldrich, St Louis, MO, USA) and photographed under UV transillumination (Vilber Lourmat, Marne La Valée, France).

All primer pairs used in this study were synthesized in the Laboratory of DNA Sequencing and Oligonucleotide Synthesis, Institute of Biochemistry and Biophysics PAN, Warsaw, Poland.

Sequencing of polymerase chain reaction products {#S20006}
------------------------------------------------

Based on agarose gel analysis, samples positive for human HLA-B27, -B40 and -B47:01 genes were selected and sequenced (automated fluorescence-based sequencing) using the HLA-B27-specific MW16 primer \[[@CIT0006]\]. Sequencing was performed in the Genomed Laboratory, Warsaw, Poland. The MW16 sequence is located in exon 2 of the HLA-B27 gene. Obtained sequences were about 600 bp long and covered part of exon 2, intron 2 and part of exon 3 ([Table I](#T0001){ref-type="table"}). DNA concentration in sequenced samples was 40 ng/ml, and MW16 primer concentration was 5 µM. Obtained sequences were analysed using Chromas LITE 2.1.1 software (Technelysium Pty Ltd, South Brisbane, Australia), BLAST software (National Library of Medicine, Bethesda, MD, USA) and the IMGT/HLA database ([www.ebi.ac.uk/ipd/imgt/hla/](http://www.ebi.ac.uk/ipd/imgt/hla/)).

Results {#S0007}
=======

The results of flow cytometry analysis showed that among 300 samples, 76 were HLA-B27-positive ([Table II](#T0002){ref-type="table"}). Genetic sequence analysis confirmed the positivity of 73 from among these 76 samples. 226 samples were negative, whereas one sample was impossible to interpret using the sequence-based method. The sequencing revealed that 53 samples were allelic variant 27:05, 19 samples were 27:02 and 1 sample was 27:07.

###### 

Results of HLA-B27 detection analysis in 300 patients with suspected spondyloarthropathy

  -------------------------------------------------
  HLA-B27     Flow cytometry   PCR and sequencing
  ----------- ---------------- --------------------
  Positive\   76               73\
  27:05\                       53\
  27:02\                       19\
  27:07                        1

  Negative    224              226

  Ambiguous                    1
  -------------------------------------------------

In samples 56, 162 and 355, HLA-B27 was detected by flow cytometry, but was impossible to detect on the basis of the genetic method ([Figs. 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"}). Polymerase chain reaction using MW02 and MW09 primers generated a 666-bp product in sample 56, but sequencing excluded the HLA-B27 gene. This result was inconsistent with the GS145.2 antibody assay. Interestingly, PCR performed using E91 and E136 primers proved HLA-B27 gene presence in sample 56 ([Fig. 2](#F0002){ref-type="fig"}). In the case of samples 162 and 355, the PCR with both primer pairs did not generate any products, which indicates that the donors were HLA-B27/B40/B47:01-negative ([Figs. 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"}). β-globin gene detection in these samples excluded false negative results ([Fig. 1A](#F0001){ref-type="fig"}). Three incoherent results are summarized in [Table III](#T0003){ref-type="table"}.

![Products of PCR amplifying HLA-B27, -B40, -B47:01 and β-globin genes. Agarose gel (1.5%) electrophoresis. A -- HLA-B27-negative samples no. 162 and 355. B -- exemplary HLA-B27-positive samples no. 4, 28 and 36.](RU-53-51506-g001){#F0001}

![PCR products generated using E91 and E136 primers. Agarose gel (2%) electrophoresis; DNA isolated from samples no. 56, 162, 355 and from exemplary HLA-B27-positive sample no. 36. A -- HLA-B27 gene amplification. B -- β-globin gene amplification. DNA ladder ranges from 100 to 1000 bp.](RU-53-51506-g002){#F0002}

###### 

Samples giving incoherent results

  Sample no.   Flow cytometry   PCR MW02/MW09 and sequencing   PCR E91/E136
  ------------ ---------------- ------------------------------ --------------
  56           positive         negative                       positive
  162          positive         negative                       negative
  355          positive         negative                       negative

Discussion and conclusions {#S0008}
==========================

The flow cytometry assay and sequence-based method used in this study bring consistent results in 99% of cases. The flow cytometry assay can give false negative results due to the cross-reactivity of GS145.2 antibody with HLA-B07 \[[@CIT0008]\], which may explain the incoherent results in the case of samples 162 and 355 ([Figs. 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"}). Although MW02/MW09 and E91/E136 primer pairs used in this study do not anneal with every HLA-B27 allelic variant ([Table I](#T0001){ref-type="table"}), the application of both pairs ensured potential detection of all subtypes.

Results obtained for sample 56 are difficult to interpret ([Table III](#T0003){ref-type="table"}, [Fig. 2](#F0002){ref-type="fig"}). PCR using MW02/MW09 primers and sequencing suggest that the donor of this sample is the carrier of HLA-B40 or HLA-B47:01, but the flow cytometry analysis proved the presence of HLA-B27. The possible explanation of these contradictory results may be the fact that GS145.2 antibody also cross-reacts with HLA-B40 \[[@CIT0008]\]. Nevertheless, PCR with E91/E136 primers indicates that the donor may be a carrier of the HLA-B27 gene. The E91/E136 primer sequences are located in exon 3, whereas the MW16 primer (used for sequencing) is located in exon 2 of the HLA-B27 gene. Thus, we can speculate that the donor might carry some mutations in exon 2 which precluded annealing of the MW16 primer, but did not affect recognition of the epitope by GS145.2 antibody. It is known that there are only a few specific amino acid residues crucial for GS145.2 antibody binding to HLA-B27 \[[@CIT0009]\].

The performed genetic analysis proved that all positive samples belong to the three most popular HLA-B27 subtypes in the Polish population: 27:05, 27:02 and 27:07 \[[@CIT0004]\]. As already mentioned, the risk of AS is not the same for every HLA-B27 carrier and is associated with particular allelic variants of HLA-B27. Cytometric analysis revealed that 76 patients were HLA-B27-positive, but as a result of the genetic analysis we were able to demonstrate that in the vast majority of positive patients (*n* = 53), the 27:05 allelic variant was present. Because this subtype strongly correlates with great risk of AS \[[@CIT0003]\], we can conclude that the sequence-based method enables better and more reliable diagnosis of this disease.

This study was supported by the grant "Development of innovative test in the area of genetics based on the NGS technology" no. UDA-POIG.01.04.00-30-027/12-00 co-financed by the European Union under the European Regional Development Fund -- Activity 1.4, Innovative Economy Operational Program.

The authors declare no conflict of interest.
